NCT03752723 - Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

May 11, 2023

Study Completion Date

May 11, 2023

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

GX-I7

i.m.

DRUG

Pembrolizumab(KEYTRUDA®)

i.v.

DRUG

Cyclophosphamide

i.v.

Trial Locations (12)

Seoul National University Bundang Hospital, Seongnam-si

Ajou Medical Center, Suwon

National Cancer Center, Goyang-si

Gachon University Gil Medical Center, Incheon

Asan Medical Center, Seoul

Ewha Womans University Mokdong Hospital, Seoul

Gangnam Severance Hospital, Seoul

Korea University Anam Hospital, Seoul

Korea University Guro Hospital, Seoul

Samsung Medical Center, Seoul

Seoul ST.Mary's Hospital, Seoul

Severance Hospital, Seoul